Holen Sie sich die Stockscreener-App
2.31
3.59%
0.08
Handel nachbörslich:
2.31
Schlusskurs vom Vortag:
$2.23
Offen:
$2.21
24-Stunden-Volumen:
32,464
Relative Volume:
0.76
Marktkapitalisierung:
$16.21M
Einnahmen:
$2.43M
Nettoeinkommen (Verlust:
$-11.03M
KGV:
0.0363
EPS:
63.6476
Netto-Cashflow:
$-3.75M
1W Leistung:
+14.93%
1M Leistung:
+4.52%
6M Leistung:
-55.06%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.21
$2.375
1-Wochen-Bereich:
$1.9348
$2.375
52-Wochen-Spanne:
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Firmenname
Vyome Holdings Inc
Sektor
Branche
Telefon
949-429-6680
Adresse
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.31 | 15.65M | 2.43M | -11.03M | -3.75M | 63.65 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyome Holdings Inc Aktie (HIND) Neueste Nachrichten
Vyome Holdings Inc. (HIND) Q4 2025 Earnings: Significant EPS Beat Highlights Cost DisciplineProfessional Trade Ideas - Newser
Vyome Holdings (HIND) Stock Analysis: -1.56% Loss — Key Levels 2026-05-15Retail Trader Ideas - Newser
Vyome Holdings inks agreement with Impetis Biosciences to in-license two selective JAK inhibitor assets - BioSpectrum India
Vyome secures exclusive license from Impetis for selective JAK inhibitor programs - Indian Pharma Post
Vyome Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vyome strikes deal with Impetis Biosciences, opening a ~$57B market opportunity - marketscreener.com
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity - The Joplin Globe
How Vyome Holdings (HIND) compares to the market average (Weakens) 2026-05-08Put Flow Alert - Newser
HIND Stock Price, Quote & Chart | VYOME HOLDINGS INC (NASDAQ:HIND) - ChartMill
HIND (Vyome Holdings) shares fall 2.86% despite Q4 2025 EPS beating analyst estimates by a wide 40% margin.Stock Market Community - newser.com
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings - Indian Pharma Post
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings, Inc. - Indian Pharma Post
What could go wrong with Vyome Holdings (HIND) stock | Q4 2025: Earnings Beat EstimatesBeat Estimates - newser.com
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 - BioSpace
Maxim Group Maintains Vyome Holdings(HIND.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Vyome reports positive phase 2 results for cancer wound treatment By Investing.com - Investing.com Australia
Vyome reports positive phase 2 results for cancer wound treatment - Investing.com
HIND Financials: Income Statement, Balance Sheet & Cash Flow | Vyome Holdings, Inc. - Stock Titan
Vyome Holdings (HIND) Stock Consolidates (Eye on Rally) 2026-04-20Social Trading Insights - Xã Châu Thành
Vyome Holdings (HIND) Stock: Why Institutions Watch It (Ticks Lower) 2026-04-18Shared Trade Ideas - Xã Thanh Hà
Vyome Holdings (STU:24O0) PB Ratio : 0.00 (As of Apr. 16, 2026) - GuruFocus
Vyome Holdings, Inc. (HIND) stock price, news, quote and history - Yahoo Finance UK
Breaking News about Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) - FinancialContent
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 - BioSpace
Vyome to present VT-1953 Phase 2 data at cancer research meeting By Investing.com - Investing.com South Africa
Vyome to present VT-1953 Phase 2 data at cancer research meeting - Investing.com
HIND Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027 - Indian Pharma Post
RSLS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
HIND Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase - Business Wire
Vyome Holdings, Inc.: Fundamental Analysis and Financial Ratings | H1O | US92943X1046 - marketscreener.com
Vyome Holdings Reports Positive Phase 2 Clinical Results for VT-1953 Topical Gel in Malignant Fungating Wounds and Acne Treatment – 2026 Company Overview and Pipeline Update - Minichart
Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Vyome 10-K: $0.32M Revenue, $(4.86) Loss per Share - TradingView
Vyome (HIND) versus Its Competitors Critical Analysis - Defense World
Head-To-Head Comparison: Vyome (HIND) versus The Competition - Defense World
Vyome (HIND) vs. Its Rivals Head to Head Contrast - Defense World
Vyome (HIND) & The Competition Head to Head Analysis - Defense World
Reviewing Vyome (HIND) and Its Rivals - Defense World
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Stocktwits
RSLS SEC FilingsReShape Lifesciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Vyome (HIND) & Its Peers Financial Survey - Defense World
Critical Comparison: Vyome (HIND) versus The Competition - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Finanzdaten der Vyome Holdings Inc-Aktie (HIND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):